JP2006524331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524331A5 JP2006524331A5 JP2006507518A JP2006507518A JP2006524331A5 JP 2006524331 A5 JP2006524331 A5 JP 2006524331A5 JP 2006507518 A JP2006507518 A JP 2006507518A JP 2006507518 A JP2006507518 A JP 2006507518A JP 2006524331 A5 JP2006524331 A5 JP 2006524331A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- calgranulin
- infection
- amniotic
- maternal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 197
- 102000004169 proteins and genes Human genes 0.000 claims description 190
- 208000008158 Chorioamnionitis Diseases 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 63
- 238000012360 testing method Methods 0.000 claims description 56
- 210000002966 serum Anatomy 0.000 claims description 49
- 239000013060 biological fluid Substances 0.000 claims description 43
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 34
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 33
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims description 32
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims description 32
- 238000003745 diagnosis Methods 0.000 claims description 27
- 238000001819 mass spectrum Methods 0.000 claims description 22
- 108010039659 FALL 39 Proteins 0.000 claims description 16
- 210000004381 amniotic fluid Anatomy 0.000 claims description 16
- 230000002797 proteolythic effect Effects 0.000 claims description 16
- 210000000440 neutrophil Anatomy 0.000 claims description 15
- 102000016453 Macrophage-capping proteins Human genes 0.000 claims description 13
- 108050006096 Macrophage-capping proteins Proteins 0.000 claims description 13
- 102100032420 Protein S100-A9 Human genes 0.000 claims description 13
- 108010049148 plastin Proteins 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 13
- 108010052495 Calgranulin B Proteins 0.000 claims description 12
- 102100035182 Plastin-2 Human genes 0.000 claims description 12
- 238000001262 western blot Methods 0.000 claims description 12
- 102000011195 Profilin Human genes 0.000 claims description 11
- 108050001408 Profilin Proteins 0.000 claims description 11
- 108010052500 Calgranulin A Proteins 0.000 claims description 9
- 102000013382 Gelatinases Human genes 0.000 claims description 9
- 108010026132 Gelatinases Proteins 0.000 claims description 9
- 102100032442 Protein S100-A8 Human genes 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 238000003498 protein array Methods 0.000 claims description 9
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims description 8
- 102000019298 Lipocalin Human genes 0.000 claims description 8
- 108050006654 Lipocalin Proteins 0.000 claims description 8
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 8
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 8
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims description 7
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims description 7
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 claims description 7
- 102000004878 Gelsolin Human genes 0.000 claims description 6
- 108090001064 Gelsolin Proteins 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 102100028233 Coronin-1A Human genes 0.000 claims description 5
- 108010061641 Cystatin A Proteins 0.000 claims description 5
- 102100031237 Cystatin-A Human genes 0.000 claims description 5
- 102100033299 Glia-derived nexin Human genes 0.000 claims description 5
- 102100027869 Moesin Human genes 0.000 claims description 5
- 108010071525 moesin Proteins 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 claims description 4
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 claims description 4
- 108010063045 Lactoferrin Proteins 0.000 claims description 4
- 102100032241 Lactotransferrin Human genes 0.000 claims description 4
- 102100036383 Serpin B3 Human genes 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 235000020256 human milk Nutrition 0.000 claims description 4
- 210000004251 human milk Anatomy 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 claims description 3
- 101710183121 14-3-3 protein zeta/delta Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000004149 Annexin A2 Human genes 0.000 claims description 3
- 108090000668 Annexin A2 Proteins 0.000 claims description 3
- 102000004411 Antithrombin III Human genes 0.000 claims description 3
- 108090000935 Antithrombin III Proteins 0.000 claims description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
- 108010061642 Cystatin C Proteins 0.000 claims description 3
- 102100026897 Cystatin-C Human genes 0.000 claims description 3
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims description 3
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 claims description 3
- 102100030326 Serpin B4 Human genes 0.000 claims description 3
- 102000014701 Transketolase Human genes 0.000 claims description 3
- 108010043652 Transketolase Proteins 0.000 claims description 3
- 229960005348 antithrombin iii Drugs 0.000 claims description 3
- 108010061635 Cystatin B Proteins 0.000 claims description 2
- 102100026891 Cystatin-B Human genes 0.000 claims description 2
- 102100037389 Phosphoglycerate mutase 1 Human genes 0.000 claims description 2
- 108050006040 Phosphoglycerate mutase 1 Proteins 0.000 claims description 2
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 claims description 2
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 claims description 2
- 102000035118 modified proteins Human genes 0.000 claims description 2
- 108091005573 modified proteins Proteins 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 148
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 127
- 230000008774 maternal effect Effects 0.000 description 98
- 241001494479 Pecora Species 0.000 description 83
- 239000000523 sample Substances 0.000 description 72
- 208000015181 infectious disease Diseases 0.000 description 66
- 230000001605 fetal effect Effects 0.000 description 47
- 238000004458 analytical method Methods 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 40
- 238000001514 detection method Methods 0.000 description 31
- 206010056254 Intrauterine infection Diseases 0.000 description 28
- 239000000499 gel Substances 0.000 description 28
- 230000001575 pathological effect Effects 0.000 description 28
- 238000001228 spectrum Methods 0.000 description 28
- 208000036878 aneuploidy Diseases 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 230000002759 chromosomal effect Effects 0.000 description 25
- 231100001075 aneuploidy Toxicity 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 22
- 230000035935 pregnancy Effects 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 201000010099 disease Diseases 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 16
- 201000011461 pre-eclampsia Diseases 0.000 description 16
- 238000012216 screening Methods 0.000 description 16
- 201000010374 Down Syndrome Diseases 0.000 description 15
- 108010026552 Proteome Proteins 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 241000288906 Primates Species 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 239000000090 biomarker Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 206010044688 Trisomy 21 Diseases 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 11
- 208000037805 labour Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000003491 array Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 238000012384 transportation and delivery Methods 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- 206010060937 Amniotic cavity infection Diseases 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 102000008847 Serpin Human genes 0.000 description 7
- 108050000761 Serpin Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 7
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000013074 reference sample Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108010075016 Ceruloplasmin Proteins 0.000 description 6
- 102100023321 Ceruloplasmin Human genes 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 208000006816 Neonatal Sepsis Diseases 0.000 description 6
- 206010036600 Premature labour Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 208000026440 premature labor Diseases 0.000 description 6
- 238000000575 proteomic method Methods 0.000 description 6
- 238000007423 screening assay Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000003001 serine protease inhibitor Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 102100030009 Azurocidin Human genes 0.000 description 5
- 201000006360 Edwards syndrome Diseases 0.000 description 5
- 108010028275 Leukocyte Elastase Proteins 0.000 description 5
- 102000016799 Leukocyte elastase Human genes 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 5
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 5
- -1 azilocidin (CAPS7) Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000036244 malformation Effects 0.000 description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011809 primate model Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010053884 trisomy 18 Diseases 0.000 description 5
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 4
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 4
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 102100030635 Leukocyte elastase inhibitor Human genes 0.000 description 4
- 101710091916 Leukocyte elastase inhibitor Proteins 0.000 description 4
- 208000005107 Premature Birth Diseases 0.000 description 4
- 238000010847 SEQUEST Methods 0.000 description 4
- 208000026928 Turner syndrome Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 4
- 206010024378 leukocytosis Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000009984 peri-natal effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 102000004899 14-3-3 Proteins Human genes 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101710154607 Azurocidin Proteins 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 102000015833 Cystatin Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 3
- 208000035752 Live birth Diseases 0.000 description 3
- 208000034702 Multiple pregnancies Diseases 0.000 description 3
- 241000204048 Mycoplasma hominis Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 201000009928 Patau syndrome Diseases 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 208000037280 Trisomy Diseases 0.000 description 3
- 206010044686 Trisomy 13 Diseases 0.000 description 3
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000935255 Ureaplasma parvum Species 0.000 description 3
- 206010046827 Uterine tenderness Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 108010039309 actin-modulating proteins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 206010008129 cerebral palsy Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 108050004038 cystatin Proteins 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 108010000849 leukocyte esterase Proteins 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 101710112812 14-3-3 protein Proteins 0.000 description 2
- 102000000454 14-3-3 protein sigma Human genes 0.000 description 2
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 208000022471 Fetal disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003322 aneuploid effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000003785 decidua Anatomy 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 208000037824 growth disorder Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000003183 myoelectrical effect Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- NHSJCIBSNKLAMA-UHFFFAOYSA-N (2Z)-1-ethyl-2-[(2E,4E)-5-[1-[6-[2-(4-hydroxyphenyl)ethylamino]-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]penta-2,4-dienylidene]-3,3-dimethylindole-5-sulfonate Chemical compound CC[N+]1=C(\C=C\C=C\C=C2/N(CCCCCC(=O)NCCC3=CC=C(O)C=C3)C3=CC=C(C=C3C2(C)C)S(O)(=O)=O)C(C)(C)C2=C1C=CC(=C2)S([O-])(=O)=O NHSJCIBSNKLAMA-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- 108700020469 14-3-3 Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108050003114 Coronin 1A Proteins 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 101001130157 Dioclea sclerocarpa Lectin alpha chain Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- 101710191797 Gamma-enolase Proteins 0.000 description 1
- 101710183811 Glia-derived nexin Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101000824531 Homo sapiens CAAX prenyl protease 1 homolog Proteins 0.000 description 1
- 101000860852 Homo sapiens Coronin-1A Proteins 0.000 description 1
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010053584 Neonatal pneumonia Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710188688 Non-structural protein 7a Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710156990 Protein S100-A9 Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100025517 Serpin B9 Human genes 0.000 description 1
- 208000027583 Serpinopathy Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007976 Tris-NaCl-Tween buffer Substances 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108010067471 inhibin A Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009602 intrauterine growth Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 244000123579 maile Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 201000005936 periventricular leukomalacia Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229930192033 plastin Natural products 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/400,005 US7191068B2 (en) | 2003-03-25 | 2003-03-25 | Proteomic analysis of biological fluids |
| PCT/US2004/008954 WO2004088324A2 (en) | 2003-03-25 | 2004-03-23 | Proteomic analysis of biological fluids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010044772A Division JP5011410B2 (ja) | 2003-03-25 | 2010-03-01 | 生体液のプロテオーム分析 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524331A JP2006524331A (ja) | 2006-10-26 |
| JP2006524331A5 true JP2006524331A5 (enExample) | 2010-04-22 |
Family
ID=33096805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507518A Ceased JP2006524331A (ja) | 2003-03-25 | 2004-03-23 | 生体液のプロテオーム分析 |
| JP2010044772A Expired - Fee Related JP5011410B2 (ja) | 2003-03-25 | 2010-03-01 | 生体液のプロテオーム分析 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010044772A Expired - Fee Related JP5011410B2 (ja) | 2003-03-25 | 2010-03-01 | 生体液のプロテオーム分析 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7191068B2 (enExample) |
| EP (2) | EP2088433A1 (enExample) |
| JP (2) | JP2006524331A (enExample) |
| CN (1) | CN1795387A (enExample) |
| AT (1) | ATE423322T1 (enExample) |
| AU (2) | AU2004225527B2 (enExample) |
| CA (1) | CA2560972A1 (enExample) |
| DE (1) | DE602004019511D1 (enExample) |
| DK (1) | DK1618388T3 (enExample) |
| ES (1) | ES2322593T3 (enExample) |
| MX (1) | MXPA05010325A (enExample) |
| WO (1) | WO2004088324A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006511790A (ja) * | 2002-11-14 | 2006-04-06 | サイファージェン バイオシステムズ インコーポレイテッド | 羊膜内炎症のためのバイオマーカー |
| US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| US8068990B2 (en) * | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
| GB0313828D0 (en) | 2003-06-16 | 2003-07-23 | Owen Smith Brian D O | Salivary urate for diagnosis of pre-eclampsia |
| US8165661B2 (en) * | 2003-08-21 | 2012-04-24 | Mcgill University | Method and apparatus for analyzing amniotic fluid |
| US20050233400A1 (en) * | 2004-03-03 | 2005-10-20 | Weiner Carl P | Proteomic method for predicting success of rescue cerclage |
| WO2005093413A2 (en) * | 2004-03-22 | 2005-10-06 | Yale University | Diagnosis and treatment of preeclampsia |
| WO2006076025A2 (en) * | 2004-05-14 | 2006-07-20 | Amaox, Inc. | Immune cell biosensors and methods of using same |
| EP2848942B1 (en) | 2004-07-14 | 2017-03-08 | The Regents of The University of California | Biomarkers for early detection of ovarian cancer |
| US7670792B2 (en) * | 2004-07-14 | 2010-03-02 | The Regents Of The University Of California | Biomarkers for early detection of ovarian cancer |
| US9488655B2 (en) * | 2004-07-14 | 2016-11-08 | The Regents Of The University Of California | Biomarkers for detection of early- and late-stage endometrial cancer |
| WO2012047930A2 (en) | 2010-10-04 | 2012-04-12 | The Regents Of The University Of California | Compositions and methods for treatment of gynecologic cancers |
| US20060094039A1 (en) * | 2004-09-20 | 2006-05-04 | Ron Rosenfeld | Diagnosis of fetal aneuploidy |
| DE602005023216D1 (de) * | 2004-12-15 | 2010-10-07 | Beth Israel Hospital | Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen |
| ATE490465T1 (de) * | 2005-01-28 | 2010-12-15 | Childrens Medical Center | Diagnose- und prognoseverfahren von blasenkrebs. |
| US7645576B2 (en) * | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| US20070087387A1 (en) * | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
| EP1937706A4 (en) * | 2005-09-09 | 2008-10-22 | Univ Iowa Res Found | ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION |
| US7312079B1 (en) | 2005-10-06 | 2007-12-25 | Lexicon Pharmaceuticals, Inc. | Variants of FAM3C |
| US20070190580A1 (en) * | 2005-10-31 | 2007-08-16 | Beckman Coulter, Inc. | Immunoassay of Fragments of Insulin-Like Growth Factor Binding Proteins |
| US7981399B2 (en) * | 2006-01-09 | 2011-07-19 | Mcgill University | Method to determine state of a cell exchanging metabolites with a fluid medium by analyzing the metabolites in the fluid medium |
| AU2007209980A1 (en) * | 2006-01-27 | 2007-08-09 | Eastern Virginia Medical School | Proteomic fingerprinting of human IVF-derived embryos: identification of biomarkers of developmental potential |
| US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| WO2007109293A2 (en) * | 2006-03-21 | 2007-09-27 | Yale University | Early diagnosis of congenital abnormalities in the offspring of diabetic mothers |
| WO2008019491A1 (en) * | 2006-08-16 | 2008-02-21 | National Research Council Of Canada | Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein |
| US20100137263A1 (en) * | 2006-10-20 | 2010-06-03 | Newcastle Innovation Limited | Assay for the detection of biomarkers associated with pregnancy related conditions |
| CA2673946C (en) * | 2006-12-26 | 2014-10-14 | Brigham Young University | Serum proteomics system and associated methods |
| WO2008112424A1 (en) * | 2007-03-08 | 2008-09-18 | Mayo Foundation For Medical Education And Research | Assessing heart failure |
| WO2008134881A1 (en) * | 2007-05-05 | 2008-11-13 | The University Of Western Ontario | Methods for the detection of preeclampsia |
| GB0711327D0 (en) * | 2007-06-12 | 2007-07-25 | Hansa Medical Ab | Diagnostic method |
| CN101802616B (zh) | 2007-07-19 | 2014-10-15 | 生物梅里埃公司 | 体外诊断结肠直肠癌的肝脂肪酸结合蛋白、cea和ca19-9测定方法 |
| FR2919063B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal. |
| FR2919065B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal |
| FR2919060B1 (fr) | 2007-07-19 | 2012-11-30 | Biomerieux Sa | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal. |
| JP5363481B2 (ja) * | 2007-07-20 | 2013-12-11 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション | 早産の危険性を評価するためのバイオマーカーの同定および定量化 |
| WO2009046447A1 (en) * | 2007-10-06 | 2009-04-09 | Katalin Polgar | Fetal open lesion detection system |
| JP2011506971A (ja) * | 2007-12-13 | 2011-03-03 | スリーエム イノベイティブ プロパティズ カンパニー | 創傷試料を解析する方法 |
| US20100016173A1 (en) * | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US20100017143A1 (en) * | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health |
| US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
| US8481273B2 (en) * | 2008-06-20 | 2013-07-09 | University Of Delaware | Perlecan fragments as biomarkers of bone stromal lysis |
| US20110247404A1 (en) * | 2008-06-25 | 2011-10-13 | University Of Utah Research Foundation | Identifying and quantifying biomarkers associated with preeclampsia |
| FR2933773B1 (fr) | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| US8476008B2 (en) | 2008-07-23 | 2013-07-02 | Diabetomics, Llc | Methods for detecting pre-diabetes and diabetes |
| WO2011053832A1 (en) * | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
| CA2780976C (en) | 2009-11-25 | 2020-03-31 | Hologic, Inc. | Detection of intraamniotic infection |
| US20130058931A1 (en) | 2010-03-11 | 2013-03-07 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pregnancy loss |
| ES2667066T3 (es) | 2010-05-24 | 2018-05-09 | The Trustees Of Columbia University In The City Of New York | Proteínas NGAL mutantes y usos de las mismas |
| EP2575862A2 (en) * | 2010-05-28 | 2013-04-10 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| GB201016161D0 (en) | 2010-09-24 | 2010-11-10 | Hansa Medical Ab | Diagnostic method |
| US20120142559A1 (en) * | 2010-12-06 | 2012-06-07 | Pronota N.V. | Biomarkers and parameters for hypertensive disorders of pregnancy |
| GB201102108D0 (en) | 2011-02-07 | 2011-03-23 | Hansa Medical Ab | Diagnostic method |
| US20140162941A1 (en) * | 2011-07-27 | 2014-06-12 | Baylor College Of Medicine | Process for preparing biological samples |
| AU2012301955A1 (en) | 2011-08-29 | 2014-03-06 | The Regents Of The University Of California | Use of HDL-related molecules to treat and prevent proinflammatory conditions |
| KR101142434B1 (ko) * | 2011-09-08 | 2012-05-08 | (주)오비메드 | 조기양막파수 산모에서 비침습적인 양수 내 염증 및 감염의 예측 또는 진단 방법 |
| CN102426243B (zh) * | 2011-11-17 | 2014-03-19 | 成都创宜生物科技有限公司 | 以补体因子d为检测指标的子痫前期检测试剂盒的制备方法 |
| US9511087B2 (en) | 2012-08-03 | 2016-12-06 | Revo Biologics, Inc. | Use of antithrombin in extracorporeal membrane oxygenation |
| ES2690782T3 (es) | 2012-10-24 | 2018-11-22 | Nyu Winthrop Hospital | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| US20140178911A1 (en) * | 2012-12-20 | 2014-06-26 | Roche Molecular Systems, Inc. | Characterization of thermostable dna polymerase |
| GB201305317D0 (en) * | 2013-03-22 | 2013-05-08 | Iles Raymond K | Prenatal screening for fetal abnormalities and disorders of pregnancy |
| WO2014210031A1 (en) | 2013-06-25 | 2014-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Proteomic biomarkers of sepsis in elderly patients |
| FR3036188B1 (fr) | 2015-05-12 | 2019-06-07 | Biomerieux | Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee |
| JP6840391B2 (ja) | 2015-06-19 | 2021-03-10 | セラ プログノスティックス， インコーポレイテッド | 早産を予測するためのバイオマーカーの対 |
| MA45272A (fr) | 2015-06-27 | 2018-05-02 | Stimlabs Llc | Produits issus de liquide amniotique et procédés d'utilisation |
| CN105372414B (zh) * | 2015-10-09 | 2017-12-22 | 成都大熊猫繁育研究基地 | 大熊猫乳汁中关键因子的分析方法 |
| CA3047607A1 (en) | 2016-12-20 | 2018-06-28 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
| WO2019036032A1 (en) | 2017-08-18 | 2019-02-21 | Sera Prognostics, Inc | PREGNANCY CLOCK PROTEINS FOR PREDICTING THE DATE AND MOMENT OF BIRTH |
| EP3682250A4 (en) | 2017-09-13 | 2021-03-03 | Progenity, Inc. | PRE-ECAMPSY BIOMARKERS AND ASSOCIATED SYSTEMS AND PROCESSES |
| US20190224277A1 (en) * | 2018-01-22 | 2019-07-25 | CyPhi LLC | Bio-mimetic formulation |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113092771A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液α-1B-糖蛋白及其多肽片段在过敏性疾病中的应用 |
| CN113092773A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液α-胰蛋白酶抑制剂重链H4及其多肽片段在过敏性疾病中的应用 |
| CN111951969A (zh) * | 2020-08-05 | 2020-11-17 | 中翰盛泰生物技术股份有限公司 | Hbp在高危妊娠预测中的应用 |
| WO2025243332A1 (en) * | 2024-05-24 | 2025-11-27 | Intignus Biotech Private Limited | Lfa device for detecting biomarkers for intrapartum and neonatal complications and method thereof |
| CN120233090B (zh) * | 2025-03-28 | 2025-09-09 | 中日友好医院(中日友好临床医学研究所) | 一组尿蛋白标志物及其在制备非小细胞肺癌预后预测产品中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5871937A (en) * | 1985-04-30 | 1999-02-16 | The Scripps Research Institute | Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides |
| US5516702A (en) * | 1991-11-06 | 1996-05-14 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for imminent delivery |
| US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| US5484705A (en) * | 1994-01-24 | 1996-01-16 | Xoma Corporation | Method for quantifying lipopolysaccharide binding protein |
| US5891618A (en) * | 1994-01-24 | 1999-04-06 | Xoma Corporation | Method for quantifying LBP in body fluids |
| US5932536A (en) * | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| US20020164818A1 (en) * | 1995-05-23 | 2002-11-07 | Gruber Karl F. | Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids |
| WO1996037777A1 (en) * | 1995-05-23 | 1996-11-28 | Nelson Randall W | Mass spectrometric immunoassay |
| AU2636399A (en) * | 1998-02-25 | 1999-09-15 | National University Of Ireland, Cork | Hla linked pre-eclampsia and miscarriage susceptibility gene |
| US6324479B1 (en) * | 1998-05-08 | 2001-11-27 | Rosetta Impharmatics, Inc. | Methods of determining protein activity levels using gene expression profiles |
| US6406921B1 (en) * | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| EP1143246A4 (en) * | 1998-12-28 | 2004-11-24 | Advance Kk | IDENTIFICATION SYSTEM OF MICROORGANISMS |
| AU3712200A (en) * | 1999-03-01 | 2000-09-21 | Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for chorioamnionitis |
| EP1166113A1 (en) * | 1999-04-07 | 2002-01-02 | Unilever Plc | Lipopolysaccharide immunoassay and test device |
| AU6615500A (en) * | 1999-07-28 | 2001-02-19 | Genetics Institute Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
| US6653151B2 (en) * | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
| WO2001040517A2 (en) * | 1999-11-30 | 2001-06-07 | Oxo Chemie Ag | Evaluating and predicting clinical outcomes by gene expression analysis |
| EP1481249A1 (en) * | 2002-03-07 | 2004-12-01 | Cambridge University Technical Services Limited | Scd fingerprints |
| CN1395103A (zh) * | 2002-07-31 | 2003-02-05 | 中华人民共和国北京出入境检验检疫局 | 疯牛病病原检测压电生物芯片及其制备方法 |
| JP2006511790A (ja) | 2002-11-14 | 2006-04-06 | サイファージェン バイオシステムズ インコーポレイテッド | 羊膜内炎症のためのバイオマーカー |
| JP2006514284A (ja) * | 2003-02-05 | 2006-04-27 | サイファージェン バイオシステムズ インコーポレイテッド | 羊水内環境の非侵襲性評価 |
| US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| WO2005017192A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
| ES2556164T3 (es) * | 2003-09-23 | 2016-01-13 | The General Hospital Corporation | Cribado de la preeclampsia |
| US20060063162A1 (en) * | 2004-09-23 | 2006-03-23 | Deng David X | Biological marker for inflammation |
| US20060078998A1 (en) * | 2004-09-28 | 2006-04-13 | Singulex, Inc. | System and methods for sample analysis |
| GB0426982D0 (en) * | 2004-12-09 | 2005-01-12 | Secr Defence | Early detection of sepsis |
| US20070092911A1 (en) * | 2005-10-03 | 2007-04-26 | Buechler Kenneth F | Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes |
| BRPI0609302A2 (pt) * | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| ATE493652T1 (de) * | 2005-08-11 | 2011-01-15 | Siemens Healthcare Diagnostics | Quantitative assays für pdgfr-beta- in körperflüssigkeiten |
| WO2007047041A2 (en) * | 2005-10-14 | 2007-04-26 | Hyperion Biotechnology, Inc. | Methods and compositions for biomarkers associated with change in physical performance |
| US7790463B2 (en) * | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| US20080031874A1 (en) * | 2006-02-06 | 2008-02-07 | Sanders Martin E | Treatment of endotoxemia using endotoxin neutralizing agents |
| JP2009536641A (ja) * | 2006-05-31 | 2009-10-15 | ハンワ ケミカル コーポレイション | Ｖｃａｍ−１特異的モノクローナル抗体 |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
-
2003
- 2003-03-25 US US10/400,005 patent/US7191068B2/en not_active Expired - Lifetime
-
2004
- 2004-03-23 ES ES04758253T patent/ES2322593T3/es not_active Expired - Lifetime
- 2004-03-23 AT AT04758253T patent/ATE423322T1/de active
- 2004-03-23 EP EP09002096A patent/EP2088433A1/en not_active Withdrawn
- 2004-03-23 WO PCT/US2004/008954 patent/WO2004088324A2/en not_active Ceased
- 2004-03-23 AU AU2004225527A patent/AU2004225527B2/en not_active Ceased
- 2004-03-23 DK DK04758253T patent/DK1618388T3/da active
- 2004-03-23 JP JP2006507518A patent/JP2006524331A/ja not_active Ceased
- 2004-03-23 CN CN200480014441.1A patent/CN1795387A/zh active Pending
- 2004-03-23 EP EP04758253A patent/EP1618388B1/en not_active Expired - Lifetime
- 2004-03-23 MX MXPA05010325A patent/MXPA05010325A/es active IP Right Grant
- 2004-03-23 DE DE602004019511T patent/DE602004019511D1/de not_active Expired - Lifetime
- 2004-03-23 CA CA002560972A patent/CA2560972A1/en not_active Abandoned
-
2006
- 2006-06-22 US US11/473,797 patent/US20090055099A1/en not_active Abandoned
-
2008
- 2008-07-08 US US12/217,687 patent/US20080299594A1/en not_active Abandoned
-
2010
- 2010-01-29 AU AU2010200352A patent/AU2010200352A1/en not_active Abandoned
- 2010-03-01 JP JP2010044772A patent/JP5011410B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5011410B2 (ja) | 生体液のプロテオーム分析 | |
| JP2006524331A5 (enExample) | ||
| US8068990B2 (en) | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids | |
| ES2677944T3 (es) | Detección de infección intraamniótica | |
| CN103038645B (zh) | 用于妊娠的高血压疾病的生物标志物 | |
| EP2300829B1 (en) | New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof | |
| JP2012516445A (ja) | 体液における新生児敗血症の検出のためのバイオマーカー | |
| JP2013531799A (ja) | 妊娠の高血圧障害についてのバイオマーカー | |
| Kumar et al. | Dynamic alteration in the vaginal secretory proteome across the early and mid-trimesters of pregnancy | |
| KR102127903B1 (ko) | 염증성 호흡기 질환의 진단용 바이오마커 | |
| Canisso et al. | Fetal-fluid proteome analyses in late-term healthy pregnant mares and in mares with experimentally induced ascending placentitis | |
| WO2021167098A1 (ja) | 胎児発育不全に対する定量的評価指標 | |
| EP1914548A1 (en) | Method for identifying women with an increased risk of preterm delivery | |
| HK1133922A (en) | Proteomic analysis of biological fluids | |
| Tan et al. | Preterm intraamniotic infection and inflammation: Search for protein biomarkers via proteomics approach | |
| HK1129926B (en) | Proteomic analysis of cervical-vaginal fluids for detecting intra-uterine infection or determining pre-term delivery risk in a pregnant female | |
| HK1173775A (en) | Detection of intraamniotic infection |